Ceramide and spingomyelin in neurological disorders
AssigneesMetabolomics Laboratory, Baker Heart & Diabete Institute, University of Texas Health Center At San Antonio, Indiana Alzheimer Disease Center and Dept. of Radiology and Imagining Sciences, Suny Downstate Medical Center, Intitute for Systems Biology, Helmholtz Zentrum Munchen-German Research Center for Environmental Health
InventorsRima F. Kaddurah-Daouk, Gregory Louie, Matthias Arnold, Rebecca A. Baillie, Xianlin Han, Andrew J. Saykin, Kwangsik Nho, Herman W. Moreno, Cory Funk, Priyanka Baloni, Gabriele Kastenmueller, Peter Meikle
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods for assessing and modulating ceramide and sphingomyelin in neurological disorders.
Claims31
1-4. (canceled)
A method for stratifying and treating a subject having a neurological disorder, or at risk of developing a neurological disorder, based on the subject's metabolic profile, the method comprising:
- analyzing a sample from a subject to determine concentration levels or ratios of one or more biomarker metabolites related to ceramide and sphingomyelin anabolism, catabolism, or homeostasis in the sample from the subject;
- determining if the subject has a metabolic defect related to disrupted ceramide and sphingomyelin anabolism, catabolism, or homeostasis, or if the subject's gut microbiome has a defect related to disrupted ceramide and sphingomyelin anabolism, catabolism, or homeostasis, or combinations thereof based on the measured concentration levels and calculated ratios of the one or more ceramide and sphingomyelin anabolism, catabolism, or homeostasis biomarker metabolites in the sample as compared to a control sample;
- stratifying the subject into a subgroup of subjects, wherein an individual subgroup of subjects is defined by a unique and specific ceramide and sphingomyelin anabolism, catabolism, or homeostasis profile based on the measured concentration levels and calculated ratios of the one or more biomarker metabolites in the sample as compared to a control sample and the biomarker metabolite defect determined for the subject.
(canceled)
(canceled)
A method for detecting a neurological disorder in a subject, the method comprising:
- analyzing a sample from a subject and a control sample from a control subject or population of subjects with normal cognition;
- measuring the concentration levels or ratios of one or more biomarker metabolites related to ceramide or sphingomyelin metabolism in the sample from the subject and the control sample;
- and
- determining the subject as having a neurological disorder or an increased risk of a neurological disorder when the concentration levels or ratios of the one or more biomarker metabolites in the sample from the subject are different from (greater than or less than) the concentration levels or ratios of the one or more biomarker metabolites in the control sample.
15-16. (canceled)
18-21. (canceled)
25-27. (canceled)
29-30. (canceled)
32-41. (canceled)
A method for detecting a neurological disorder in a subject, the method comprising:
- analyzing a sample from a subject and a control sample from a control subject or population of subjects with normal cognition;
- measuring the concentration levels of one or more enzymes related to ceramide or sphingomyelin metabolism in the sample from the subject and the control sample;
- and
- determining the subject as having a neurological disorder or an increased risk of a neurological disorder when the concentration levels of the one or more enzymes in the sample from the subject are different from (greater than or less than) the concentration levels of the one or more enzymes in the control sample.
44-45. (canceled)
47-48. (canceled)
(canceled)
Dependencies are inferred from the claim text.